Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy.


Journal

Clinical colorectal cancer
ISSN: 1938-0674
Titre abrégé: Clin Colorectal Cancer
Pays: United States
ID NLM: 101120693

Informations de publication

Date de publication:
09 2019
Historique:
received: 01 11 2018
revised: 18 02 2019
accepted: 08 04 2019
pubmed: 18 5 2019
medline: 7 7 2020
entrez: 18 5 2019
Statut: ppublish

Résumé

Previous small retrospective studies have suggested a benefit, mainly in preventing local recurrence, for postoperative radiation in nonmetastatic pathologic stage T4 colon cancers in patients who did not receive adjuvant chemotherapy. Current guidelines recommend postoperative radiation in nonmetastatic T4 colon cancers with penetration to a fixed structure, as well as for all patients with positive surgical margins. We aimed to assess the survival benefit of postoperative radiation in individuals with T4 colon cancers who received adjuvant chemotherapy. Using the National Cancer Data Base (2004-2014), we identified 20,967 and 5882 individuals with nonmetastatic pathologic stage T4 colon cancer treated with adjuvant chemotherapy who had negative or positive surgical margins, respectively. We used multivariate Cox regression to evaluate the effect of postoperative radiation on overall survival. In a secondary analysis, we stratified individuals according to chemotherapy intensity, pathologic N stage, and primary tumor location. Postoperative radiation did not improve overall survival in individuals with positive surgical margins (hazard ratio = 1.05 [95% CI, 0.96-1.16]). This lack of survival benefit was noted regardless of chemotherapy regimen used, with adjusted hazard ratios of 1.11 (95% CI, 0.94-1.31) and 0.96 (0.85-1.09) for single-agent and doublet chemotherapy, respectively. Similarly, pathologic N stage and primary tumor location did not affect survival. In individuals with negative surgical margins, there was a detrimental effect for postoperative radiation, with an adjusted hazard ratio of 1.19 (95% CI, 1.10-1.29). Postoperative radiation did not improve overall survival in individuals with pathologic stage T4 colon cancer who had either negative or positive surgical margins and who received adjuvant chemotherapy.

Sections du résumé

BACKGROUND
Previous small retrospective studies have suggested a benefit, mainly in preventing local recurrence, for postoperative radiation in nonmetastatic pathologic stage T4 colon cancers in patients who did not receive adjuvant chemotherapy. Current guidelines recommend postoperative radiation in nonmetastatic T4 colon cancers with penetration to a fixed structure, as well as for all patients with positive surgical margins. We aimed to assess the survival benefit of postoperative radiation in individuals with T4 colon cancers who received adjuvant chemotherapy.
METHODS
Using the National Cancer Data Base (2004-2014), we identified 20,967 and 5882 individuals with nonmetastatic pathologic stage T4 colon cancer treated with adjuvant chemotherapy who had negative or positive surgical margins, respectively. We used multivariate Cox regression to evaluate the effect of postoperative radiation on overall survival. In a secondary analysis, we stratified individuals according to chemotherapy intensity, pathologic N stage, and primary tumor location.
RESULTS
Postoperative radiation did not improve overall survival in individuals with positive surgical margins (hazard ratio = 1.05 [95% CI, 0.96-1.16]). This lack of survival benefit was noted regardless of chemotherapy regimen used, with adjusted hazard ratios of 1.11 (95% CI, 0.94-1.31) and 0.96 (0.85-1.09) for single-agent and doublet chemotherapy, respectively. Similarly, pathologic N stage and primary tumor location did not affect survival. In individuals with negative surgical margins, there was a detrimental effect for postoperative radiation, with an adjusted hazard ratio of 1.19 (95% CI, 1.10-1.29).
CONCLUSION
Postoperative radiation did not improve overall survival in individuals with pathologic stage T4 colon cancer who had either negative or positive surgical margins and who received adjuvant chemotherapy.

Identifiants

pubmed: 31097386
pii: S1533-0028(18)30520-6
doi: 10.1016/j.clcc.2019.04.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-230.e2

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Ofer Margalit (O)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Ronac Mamtani (R)

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Yaacov R Lawrence (YR)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel; Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.

Yu-Xiao Yang (YX)

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Kim A Reiss (KA)

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

Talia Golan (T)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Naama Halpern (N)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Dan Aderka (D)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Bruce Giantonio (B)

Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Einat Shacham-Shmueli (E)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.

Ben Boursi (B)

Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: ben.boursi@sheba.health.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH